Summary. Osteoporosis has become a global public health issue due to the fact that the world population has gotten older. In the past ten years we have witnessed a great improvement in the treatment of postmenopausal osteoporosis. The anti- resorptive drugs are the most presribed ones. In the last couple of years osteoanabolic drug, a teriparatid, was introduced into the clinical use, and recently a strontium ranelate has occured as a drug with osteoanabolic and antiresorptive effect in bone formation. Clinical trials (phase III) have proved the efficiency of strontium ranelate in postmenopausal osteoporosis treat- ment. Strontium ranelate is a drug characterized by the new paradigm of action mechanism on bone, which has its place among the already well-proven drugs in postmenopausal osteoporosis treatment.